EMG
GLMD icon

ETF Managers Group’s Galmed Pharmaceuticals GLMD Stock Holding History

ETF Managers Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-404
Closed -$254K – 628
2020
Q3 		$254K Buy
404
+32
+9% +$26.1K 0.01% 547
2020
Q2 		$324K Buy
372
+141
+61% +$119K 0.01% 370
2020
Q1 		$143K Buy
231
+21
+10% +$20K 0.01% 500
2019
Q4 		$216K Sell
210
-50
-19% -$42.9K 0.01% 511
2019
Q3 		$228K Buy
260
+9
+4% +$9.03K 0.01% 348
2019
Q2 		$282K Buy
251
+64
+34% +$82.5K 0.01% 292
2019
Q1 		$274K Sell
187
-6
-3% -$8.72K 0.01% 269
2018
Q4 		$237K Buy
193
+64
+50% +$112K 0.01% 282
2018
Q3 		$316K Buy
+129
New +$302K 0.01% 231
2018
Q2 		– Sell
-84
Closed -$76K – 533
2018
Q1 		$76K Buy
84
+14
+20% +$20.4K ﹤0.01% 401
2017
Q4 		$119K Buy
+70
New +$103K 0.01% 225

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

ETF Managers Group's GLMD Position: Q4 2020 in Review

ETF Managers Group sold out of Galmed Pharmaceuticals (GLMD) in Q4 2020, closing a stake of 404 shares — an estimated $254K sold.

ETF Managers Group first reported a position in GLMD in Q4 2017 and held it in 11 quarters. The position peaked at $324K in Q2 2020. 21 funds tracked by Wall St. Rank hold GLMD as of Q4 2020.

  • ETF Managers Group reported no remaining Galmed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • ETF Managers Group sold 404 Galmed Pharmaceuticals shares in Q4 2020, an estimated $254K.
  • ETF Managers Group first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • ETF Managers Group's Galmed Pharmaceuticals position peaked at $324K in Q2 2020.
  • 21 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2020.

Based on ETF Managers Group's 13F filing for Q4 2020, filed 16 Feb 2021.